Modes of resistance to anti-angiogenic therapy

The Hallmarks of Cancer

2000 • 27,569 citations

Isolation of Putative Progenitor Endothelial Cells for Angiogenesis

1997 • 8,673 citations

Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis

1996 • 6,878 citations

Targeting HIF-1 for cancer therapy

2003 • 6,321 citations

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

2005 • 5,086 citations

Angiogenesis in life, disease and medicine

2005 • 3,331 citations

Tumour-educated macrophages promote tumour progression and metastasis

2004 • 3,259 citations

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

2005 • 3,066 citations

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

2007 • 3,010 citations

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

2004 • 2,534 citations

A quantitative analysis of kinase inhibitor selectivity

2008 • 2,334 citations

Pegaptanib for Neovascular Age-Related Macular Degeneration

2004 • 2,218 citations

Angiogenesis: an organizing principle for drug discovery?

2007 • 2,179 citations

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

2007 • 1,742 citations

VEGF-targeted therapy: mechanisms of anti-tumour activity

2008 • 1,604 citations

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

2005 • 1,578 citations

The role of myeloid cells in the promotion of tumour angiogenesis

2008 • 1,574 citations

The role of pericytes in blood-vessel formation and maintenance

2005 • 1,437 citations

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors

2005 • 1,266 citations

A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF

1998 • 1,239 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,236 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,172 citations

VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells

2006 • 1,122 citations

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

2004 • 1,111 citations

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

2008 • 1,071 citations

Endothelial-pericyte interactions in angiogenesis

2003 • 1,022 citations

Integrins in angiogenesis and lymphangiogenesis

2008 • 991 citations

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

2008 • 973 citations

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

2005 • 930 citations

Mechanisms of adverse effects of anti-VEGF therapy for cancer

2007 • 914 citations

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.

1997 • 832 citations

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

2007 • 831 citations

DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

2006 • 813 citations

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

2006 • 776 citations

Cellular abnormalities of blood vessels as targets in cancer

2004 • 753 citations

A microenvironmental model of carcinogenesis

2007 • 689 citations

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

2002 • 638 citations

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

2007 • 614 citations

HIF-1 as a target for drug development

2003 • 607 citations

Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells.

1987 • 607 citations

Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms

2003 • 598 citations

The multifaceted circulating endothelial cell in cancer: towards marker and target identification

2006 • 576 citations

Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

2006 • 572 citations

The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis

2007 • 564 citations

PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival

2005 • 538 citations

Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression

2006 • 531 citations

SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells

2004 • 517 citations

Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption

2000 • 512 citations

A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer

2004 • 479 citations

Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities

2004 • 455 citations

Pericytes: Cell Biology and Pathology

2001 • 442 citations

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents

1991 • 441 citations

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

2002 • 427 citations

Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting

2008 • 424 citations

Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study

2007 • 421 citations

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

2001 • 401 citations

Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells

2005 • 400 citations

The hypoxic response of tumors is dependent on their microenvironment

2003 • 396 citations

The semaphorins: versatile regulators of tumour progression and tumour angiogenesis

2008 • 382 citations

Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival

2003 • 369 citations

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

2007 • 367 citations

Pericytes limit tumor cell metastasis

2006 • 336 citations

The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth

2007 • 287 citations

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

2008 • 262 citations

A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB

2007 • 240 citations

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

2001 • 238 citations

Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.

2005 • 230 citations

CCAAT/Enhancer Binding Protein α Knock-in Mice Exhibit Early Liver Glycogen Storage and Reduced Susceptibility to Hepatocellular Carcinoma

2005 • 200 citations

Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes

2006 • 175 citations

Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors

2008 • 162 citations

The HIF pathway in cancer

2005 • 161 citations

Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies

2004 • 161 citations

The genetics of pancreatic cancer

2003 • 159 citations

Differential diagnosis of pancreatic tumors using ultrasound contrast imaging

2005 • 158 citations

Control of angiogenesis by the pericyte: Molecular mechanisms and significance

1997 • 158 citations

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

2008 • 151 citations

Genetic and hypoxic regulation of angiogenesis in gliomas

2004 • 150 citations

What brings pericytes to tumor vessels?

2003 • 143 citations

Heterogeneous Vascular Dependence of Tumor Cell Populations

2001 • 139 citations

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

2008 • 136 citations

Identification of a Novel Small-Molecule Inhibitor of the Hypoxia-Inducible Factor 1 Pathway

2005 • 133 citations

Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases

2006 • 123 citations

Genetic alterations in pancreatic carcinoma.

2003 • 121 citations

Delta-like 4/Notch Signaling and Its Therapeutic Implications

2007 • 121 citations

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

2002 • 117 citations

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.

2003 • 113 citations

Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors

2005 • 105 citations

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

2003 • 93 citations

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy

2004 • 86 citations

Molecular and cellular biomarkers for angiogenesis in clinical oncology

2007 • 84 citations

Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation

2008 • 73 citations

Can tumor angiogenesis be inhibited without resistance?

2005 • 69 citations

Antiangiogenic Therapy for Cancer: An Update

2007 • 66 citations

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab

2008 • 59 citations

Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents

2007 • 58 citations

Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed

2005 • 58 citations

Pegaptanib sodium for the treatment of age-related macular degeneration

2008 • 50 citations

Monoclonal antibodies against components of the IGF system for cancer treatment.

2008 • 27 citations

A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)

2007 • 20 citations

A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy

2008 • 17 citations

A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy

2007 • 5 citations